SKYE LIFE VENTURES LTD. Financial Statements (2025 and earlier)
Company Profile
| Business Address |
5490 NOTRE DAME EST MONTREAL, QC H1N 2C4 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2019 MRQ | 12/31/2018 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 528,246 | |||
| Cash and cash equivalents | 528,246 | |||
| Other undisclosed current assets | 10,167 | |||
| Total current assets: | 538,413 | |||
| Noncurrent Assets | ||||
| Property, plant and equipment | 153,142 | |||
| Deposits noncurrent assets | 6,335 | |||
| Total noncurrent assets: | 159,477 | |||
| TOTAL ASSETS: | 697,890 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 95,365 | |||
| Accounts payable | 95,365 | |||
| Due to related parties | 4,136 | |||
| Total current liabilities: | 99,501 | |||
| Noncurrent Liabilities | ||||
| Other undisclosed liabilities | 8,612 | |||
| Total liabilities: | 108,113 | |||
| Equity | ||||
| Equity, attributable to parent | 589,777 | |||
| Common stock | 63,300 | |||
| Additional paid in capital | 1,839,253 | |||
| Accumulated other comprehensive loss | (43,749) | |||
| Accumulated deficit | (1,269,027) | |||
| Total equity: | 589,777 | |||
| TOTAL LIABILITIES AND EQUITY: | 697,890 | |||
Income Statement (P&L) (USD)
| 9/30/2019 TTM | 12/31/2018 | ||
|---|---|---|---|
| Operating expenses | (533,475) | ||
| Operating loss: | (533,475) | ||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (43,784) | ||
| Loss from continuing operations: | (577,259) | ||
| Loss before gain (loss) on sale of properties: | (577,259) | ||
| Net loss: | (577,259) | ||
| Other undisclosed net income attributable to parent | 43,784 | ||
| Net loss available to common stockholders, diluted: | (533,475) | ||
Comprehensive Income (USD)
| 9/30/2019 TTM | 12/31/2018 | ||
|---|---|---|---|
| Net loss: | (577,259) | ||
| Other comprehensive loss | (22,834) | ||
| Comprehensive loss: | (600,093) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 43,784 | ||
| Comprehensive loss, net of tax, attributable to parent: | (556,309) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.